Gossamer Bio, Inc.GOSSEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics for patients with serious immunology, inflammation and oncology conditions. It advances a pipeline of proprietary product candidates across multiple clinical phases, primarily serving healthcare markets in North America and other global regions.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Growth Equity Opportunities 18 VGE, LLC | 8.20% | 18.8M | — | 2023-07-28 |
| Invus Public Equities, L.P. | 5.90% | 13.5M | ▼ -0.40pp | 2024-11-12 |
| The Vanguard Group | 5.16% | 11.6M | — | 2024-02-13 |
| BlackRock, Inc. | 4.90% | 4.7M | — | 2023-05-05 |
| FMR LLC | 3.51% | 7.9M | ▼ -1.93pp | 2024-11-12 |
| Hillhouse Investment Management, Ltd. | 2.20% | 5.0M | — | 2024-02-14 |
| Millennium Management LLC | 1.90% | 4.2M | — | 2024-01-11 |
| STATE STREET CORPORATION | 1.39% | 38.3K | — | 2023-05-10 |
| ARCH | — | — | — | 2024-02-09 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
No transactions match these filters.